The influence of the dopaminergic agent 2-bromoergocryptine on plasma aldosterone response to acute stimulations was assessed in 14 normal male volunteers. Without modifying basal plasma aldosterone levels or urinary aldosterone excretion, bromocriptine retarded and diminished significantly the plasma aldosterone response to angiotensin II or ACTH, but did not alter the response to upright posture. These results point to a bromocriptineinduced modulation of the plasma aldosterone response to direct stimulations at the adrenal level. The present work brings further evidence for an effect of the dopaminergic system on the physiological control of aldosterone.
Reports on the influence of bromocriptine on aldosterone regulation are controversial. Edwards et al. (1975) found that prior treatment with bromo¬ criptine blocked the rise of plasma aldosterone induced by volume depletion. Other investigators did not observe an effect of bromocriptine on the stim¬ ulation of aldosterone induced by the progressive rise of potassium between dialyses (Olgaard et al. 1976) , by postural changes (Del Pozo et al. 1977) or by sodium deprivation (Semple 8c Mason 1978). These contradictory findings prompted the present study which was designed to evaluate the effect of bromocriptine administration on the response of the renin-angiotensin-aldosterone system to stimulation by upright posture, ACTH and angiotensin II (A II) in normal subjects.
PROTOCOLS AND METHODS
The study protocols were approved by the institutional Ethics Committee. Fourteen healthy male volunteers aged from 25 to 32 years gave their informed consent for the studies. They were on unrestricted sodium and potassium diet and continued their usual activity except during the tests.
Bromocriptine treatment. 20, 30, 60, 75, 90 and 120 min after the beginning of the A II infusion. 
RESULTS
Effect of bromocriptine treatment (Table 1) .
After 3 days of bromocriptine administration no change in body weight, mean arterial blood pressure, urinary aldosterone and electrolytes occurred. There was a discrete but not significant decrease of mean plasma renin activity. Plasma prolactin values became suppressed in all subjects, decreasing from 9.09 ± 1.06 ng/ml to 1.37 ± 0.19 ng/ml (P < 0.001). Plasma aldosterone and renin activity response to upright posture, before and 4th day of bromocriptine administration (n = 6, mean ± sem). The means in the 2 groups are not significantly different (paired ¿-test). Stimulation by upright posture (Fig. 1) . With upright posture, plasma aldosterone and renin activity increased signif¬ icantly (P < 0.05) and similarly in the untreated and treated subjects. Stimulation by ACTH (Fig. 2) .
Plasma aldosterone increased significantly in both groups (P <0.01), but the increase was sluggish in the treated subjects, the difference of mean values being statistically significant at 10, 20, and 30 min when compared with con¬ trols. Cortisol increased similarly in both groups. Plasma renin activity de¬ creased progressively and similarly from 2.16 ± 0.28 to 1.73 ± 0.24 in the untreated group and from 1.67 ± 0.34 to 1.32 ± 0.27 in the treated group (N.S.). Plasma prolactin levels remained suppressed.
Stimulation by A II (Fig. 3 Fig. 3 . Plasma aldosterone and renin activity response to A II infusion in 6 subjects on the 4th day of bromocriptine administration. Shaded area: response in 18 untreated subjects receiving 7 ng/kg/min A II from 0 to 120 min (mean ± sem). The differences of the means between the 2 groups are highly significant at 10, 20, 30, 60 and 120 min ( < 0.01, unpaired í-test).
14 ng/kg/min (2 subjects) in order to achieve a 20 mm Hg blood pressure rise. At 120 min the mean aldosterone value was still significantly lower in the treated group (P<0.01), but in 2 of the subjects receiving a higher infusion rate (10.5 (Figs. 2 and 3) . The dopaminergic action of bromocriptine appears therefore to interfere only early on aldo¬ sterone as shown by the delayed response to the two direct stimuli studied. Two observations speak in favour of an effect at the adrenal level: the absence of correlation between plasma aldosterone and renin activity in bromocriptine treated subjects, which rules out a mediation by the renin-angiotensin system (Edwards et al. 1975 ) and the rise of plasma aldosterone obtained after metoclopramide, a dopamine-receptor blocking agent, in normal and in hypophysectomized subjects (Norbiato et al. 1977ß, ) A central effect of bromocriptine on the factors regulating blood pressure is suggested by the finding that in hypertensive patients with high prolactin levels, bromocriptine suppressed prolactin and lowered blood pressure. This hypotensive effect is much less pronounced in hypertensive patients with normal plasma prolactin (Stumpe et al. 1977) and was absent in our normotensive subjects.
The absence of a significant effect of bromocriptine on the aldosterone re¬ sponse to upright posture suggests that the alleged dopaminergic influence on aldosterone secretion can be overruled by other regulatory systems.
In conclusion, the lowered and delayed response of aldosterone to iv adminis¬ tration of A II or ACTH points to a modulating effect of bromocriptine at the adrenal level. To determine whether this dopaminergic effect is direct or in¬ direct would require further studies such as with isolated adrenal gland.
